6 years of historical data (2019–2024) · Technology · Software - Infrastructure
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Core Scientific, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $5.2B | $3.6B | — | — | — | — | — |
| Enterprise Value | $5.6B | $4.0B | — | — | — | — | — |
| P/E Ratio → | -3.30 | — | — | — | — | — | — |
| P/S Ratio | 10.25 | 7.04 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | 122.00 | 83.79 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Core Scientific, Inc.'s enterprise value stands at 55.5x EBITDA, 41% above its 5-year average of 39.2x. The Technology sector median is 15.7x, placing the stock at a 252% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.75 | — | — | — | — | — |
| EV / EBITDA | 55.45 | 39.22 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Core Scientific, Inc. earns an operating margin of -3.8%. Operating margins have expanded from -329.5% to -3.8% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 23.7% | 23.7% | 24.6% | 1.3% | 43.9% | 15.6% | 17.7% |
| Operating Margin | -3.8% | -3.8% | 1.8% | -329.5% | 30.6% | -10.5% | -19.6% |
| Net Profit Margin | -257.5% | -257.5% | -49.1% | -335.2% | 8.7% | -20.2% | -20.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -460.7% | 6.4% | -9.1% | -8.8% |
| ROA | -113.8% | -113.8% | -32.4% | -132.2% | 3.6% | -6.3% | -7.4% |
| ROIC | — | — | 3.1% | -191.2% | 11.3% | -3.1% | — |
| ROCE | -2.3% | -2.3% | 2.1% | -154.0% | 14.7% | -4.2% | -8.2% |
Solvency and debt-coverage ratios — lower is generally safer
Core Scientific, Inc. carries a Debt/EBITDA ratio of 11.9x, which is highly leveraged (301% above the sector average of 3.0x). Net debt stands at $364M ($1.2B total debt minus $836M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.61 | 0.30 | 0.06 |
| Debt / EBITDA | 11.89 | 11.89 | 8.21 | — | 4.09 | 13.10 | — |
| Net Debt / Equity | — | — | — | — | 0.52 | 0.24 | 0.01 |
| Net Debt / EBITDA | 3.60 | 3.60 | 7.73 | — | 3.50 | 10.28 | — |
| Debt / FCF | — | — | 16.65 | — | — | — | — |
| Interest Coverage | -0.52 | -0.52 | 0.10 | -21.79 | 3.76 | -1.43 | -49.73 |
Short-term solvency ratios and asset-utilisation metrics
Core Scientific, Inc.'s current ratio of 6.72x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.46x to 6.72x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 6.72 | 6.72 | 0.20 | 0.46 | 2.36 | 1.02 | 0.57 |
| Quick Ratio | 6.72 | 6.72 | 0.20 | 0.46 | 2.36 | 1.02 | 0.57 |
| Cash Ratio | 6.21 | 6.21 | 0.10 | 0.09 | 0.37 | 0.12 | 0.34 |
| Asset Turnover | — | 0.32 | 0.71 | 0.79 | 0.22 | 0.27 | 0.37 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 0.73 | 5.20 | 2.02 | 1.13 | 6.70 | 1.76 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Core Scientific, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $256M | $380M | $341M | $233M | $43M | $43M |
Compare CORZ with 8 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CORZYou | $5B | -3.3 | 55.5 | — | 23.7% | -3.8% | — | — | 11.9 |
| MSFT | $2.9T | 28.8 | 18.1 | 40.7 | 68.8% | 45.6% | 33.3% | 27.9% | 0.4 |
| ORCL | $408B | 33.5 | 21.0 | — | 70.5% | 30.8% | 82.4% | 12.8% | 4.4 |
| CRWV | $33B | -28.3 | — | — | 71.7% | -0.9% | -79.9% | -0.3% | — |
| NTNX | $10B | 58.9 | 45.2 | 13.8 | 86.8% | 6.8% | — | 688.9% | 6.0 |
| DOCN | $5B | 22.2 | 19.1 | 16.6 | 59.9% | 17.4% | — | 15.6% | 2.5 |
| BLZE | $217M | -8.2 | 50.5 | 11.5 | 60.9% | -13.8% | -31.8% | -14.1% | 15.3 |
| DGXX | $180M | -12.5 | 37.1 | — | -30.7% | -29.4% | -26.5% | -32.1% | 0.0 |
| TUYA | $179M | 300.0 | — | 2.7 | 47.4% | -15.9% | 0.5% | -8.5% | — |
| Technology Median | — | 25.2 | 15.7 | 17.3 | 49.8% | -0.9% | 1.1% | 2.9% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CORZ stacks up against sector leader Microsoft Corporation.
Start ComparisonCore Scientific, Inc.'s current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
Core Scientific, Inc.'s current EV/EBITDA is 55.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 39.2x.
Based on historical data, Core Scientific, Inc. is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Core Scientific, Inc. has 23.7% gross margin and -3.8% operating margin.
Core Scientific, Inc.'s Debt/EBITDA ratio is 11.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.